Literature DB >> 8133091

Increasing incidence of adenovirus disease in bone marrow transplant recipients.

P Flomenberg1, J Babbitt, W R Drobyski, R C Ash, D R Carrigan, G V Sedmak, T McAuliffe, B Camitta, M M Horowitz, N Bunin.   

Abstract

Adenovirus infections in 201 bone marrow transplant (BMT) recipients over 4 years were retrospectively reviewed. Forty-two patients (20.9%) had positive adenovirus cultures after BMT. There was a higher incidence of adenovirus infections in pediatric patients than in adults (31.3% vs. 13.6%, P = .003). In addition, the time of onset of adenovirus infection after transplant was earlier in pediatric patients (mean, < 30 days) than in adults (> 90 days). Adenovirus type 35 was the most common serotype identified. One-third of adenovirus-positive patients had definite or probable adenovirus disease. Moderate to severe acute graft-versus-host disease and isolation of adenovirus from two or more sites were significant risk factors for adenovirus disease. This report documents a higher incidence of both adenovirus infection and disease than do previous studies. Adenovirus may emerge as a more frequent pathogen as more high-risk BMT transplants are done.

Entities:  

Mesh:

Year:  1994        PMID: 8133091     DOI: 10.1093/infdis/169.4.775

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  63 in total

1.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Adenovirus type F subtype 41 causing disseminated disease following bone marrow transplantation for immunodeficiency.

Authors:  Mary A Slatter; Steven Read; Clive E Taylor; Bruce N A Crooks; Mario Abinun; Terence J Flood; Andrew J Cant; Christopher Wright; Andrew R Gennery
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.

Authors:  Yeon Joo Lee; Dick Chung; Kun Xiao; Esperanza B Papadopoulos; Juliet N Barker; Trudy N Small; Sergio A Giralt; Junting Zheng; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-22       Impact factor: 5.742

4.  PCR detection of adenovirus in a bone marrow transplant recipient: hemorrhagic cystitis as a presenting manifestation of disseminated disease.

Authors:  M S Echavarria; S C Ray; R Ambinder; J S Dumler; P Charache
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

5.  Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions.

Authors:  Jinhong Ren; Nikita R Dsouza; Hui Deng; Hyun Lee; Marlene Bouvier; Michael E Johnson
Journal:  Bioorg Med Chem Lett       Date:  2018-07-29       Impact factor: 2.823

6.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

Review 7.  Adenoviruses in immunocompromised hosts.

Authors:  Marcela Echavarría
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

Review 8.  Treatment of adenovirus infections in the immunocompromised host.

Authors:  P Ljungman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-10       Impact factor: 3.267

9.  Epitopes and hemagglutination binding domain on subgenus B:2 adenovirus fibers.

Authors:  Y F Mei; G Wadell
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  2-[4,5-Difluoro-2-(2-fluorobenzoylamino)-benzoylamino]benzoic acid, an antiviral compound with activity against acyclovir-resistant isolates of herpes simplex virus types 1 and 2.

Authors:  Mårten Strand; Koushikul Islam; Karin Edlund; Christopher T Oberg; Annika Allard; Tomas Bergström; Ya-Fang Mei; Mikael Elofsson; Göran Wadell
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.